EX-23.1 3 ny20003563x1_ex23-1.htm EXHIBIT 23.1
Exhibit 23.1

Consent of Independent Registered Public Accounting Firm
 
We consent to the use of our report dated March 29, 2021, with respect to the financial statements of Kinnate Biopharma Inc., incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.
 
/s/ KPMG LLP
 
San Diego, California
March 28, 2022